Clinical Trials Directory

Trials / Completed

CompletedNCT03892369

FGF21 and Its Role in Alcohol Dependence

Physiological Effects of FGF21 in Humans and Its Pathophysiological Role in Alcohol Dependence

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
45 (actual)
Sponsor
University Hospital, Gentofte, Copenhagen · Academic / Other
Sex
Male
Age
25 Years – 65 Years
Healthy volunteers
Accepted

Summary

Plasma fibroblast growthfactor-21 (FGF21) responses to acute alcohol exposure will be evaluated in three groups: A: 15 individuals diagnosed with alcohol dependence (ICD10 code F10.2) and no alcoholic liver diseases, B: 15 healthy individuals with one or two parents with alcohol dependence, and C: 15 healthy matched controls without history of or disposition to alcohol dependence. The experimental day consists of a load of 0.5 g ethanol per kg body weight ingested from time 0-10 minutes followed by a 7 h period in which blood will be sampled with frequent intervals, rating of preference for ethanol, salt, sour, bitterly and sweets, sensations of hunger, appetite, satiety, headache, and nausea will be evaluated using visuel analogue scale and resting energy expenditure will be evaluated using indirect calorimetry.

Conditions

Interventions

TypeNameDescription
OTHEREthanolEthanol administration

Timeline

Start date
2019-09-01
Primary completion
2021-06-01
Completion
2021-09-01
First posted
2019-03-27
Last updated
2021-12-02

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03892369. Inclusion in this directory is not an endorsement.